<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1608210939
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Decryst
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FEBUXOSTAT
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        90.10
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jazeera Pharmaceutical Industries (JPI)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        QM04AA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Decryst tablets contain the active substance febuxostat and are used to treat gout, which is associated with an excess of a chemical called uric acid (urate) in the body. In some people, the amount of uric acid builds up in the blood and may become too high to remain soluble. When this happens, urate crystals may form in and around the joints and kidneys. These crystals can cause sudden, severe pain, redness, warmth and swelling in a joint (known as a gout attack). Left untreated, larger deposits called tophi may form in and around joints. These tophi may cause joint and bone damage.</p><p>Decryst works by reducing uric acid levels. Keeping uric acid levels low by taking febuxostat once every day stops crystals building up, and over time it reduces symptoms. Keeping uric acid levels sufficiently low for a long enough period can also shrink tophi.</p><p>Febuxostat 120 mg tablets is also used to treat and prevent high blood levels of uric acid that may occur when you start to receive chemotherapy for blood cancers.</p><p>When chemotherapy is given, cancer cells are destroyed, and uric acid levels increase in the blood accordingly, unless the formation of uric acid is prevented.</p><p>Decryst is for adults.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Decryst</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; If you are allergic to febuxostat or any of the other ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor before taking Decryst:</p><p>&middot;&nbsp;&nbsp;&nbsp; If you have or have had heart failure, heart problems or stroke</p><p>&middot;&nbsp;&nbsp;&nbsp; If you have or have had renal disease and/or serious allergic reaction to Allopurinol (a medication used for the treatment of Gout)</p><p>&middot;&nbsp;&nbsp;&nbsp; If you have or have had liver disease or liver function test abnormalities</p><p>&middot;&nbsp; &nbsp; If you are being treated for high uric acid levels as a result of Lesch-Nyhan syndrome (a rare inherited condition in which there is too much uric acid in the blood)</p><p>&middot;&nbsp;&nbsp;&nbsp; If you have thyroid problems.</p><p>&nbsp;</p><p>Should you experience allergic reactions to febuxostat, stop taking this medicine (see also section 4). Possible symptoms of allergic reactions might be:</p><p>&middot;&nbsp;&nbsp;&nbsp; Rash including severe forms (e.g. blisters, nodules, itchy-, exfoliative rash), itchiness</p><p>&middot;&nbsp;&nbsp;&nbsp; Swelling of limbs or face</p><p>&middot;&nbsp;&nbsp;&nbsp; Difficulties in breathing</p><p>&middot;&nbsp;&nbsp;&nbsp; Fever with enlarged lymph nodes</p><p>&middot;&nbsp;&nbsp;&nbsp; But also serious life threatening allergic conditions with cardiac and circulatory arrest.</p><p>&nbsp;</p><p>Your doctor might decide to permanently stop treatment with Decryst.</p><p>There have been rare reports of potentially life-threatening skin rashes (Stevens-Johnson Syndrome) with the use of febuxostat, appearing initially as reddish target-like spots or circular patches often with central blister on the trunk. It may also include ulcers in the mouth, throat, nose, genitals and conjunctivitis (red and swollen eyes). The rash may progress to widespread blistering or peeling of the skin.</p><p>If you have developed Stevens-Johnson Syndrome with the use of febuxostat, you must not be re-started on Decryst at any time. If you develop a rash or these skin symptoms, seek immediate advice from a doctor and tell that you are taking this medicine.</p><p>If you are having a gout attack at the moment (a sudden onset of severe pain, tenderness, redness, warmth and swelling in a joint), wait for the gout attack to subside before first starting treatment with Decryst.</p><p>For some people, gout attacks may flare up when starting certain medicines that control uric acid levels. Not everyone gets flares, but you could get a flare-up even if you are taking Decryst, and especially during the first weeks or months of treatment. It is important to keep taking Decryst even if you have a flare, as Decryst is still working to lower uric acid. Over time, gout flares will occur less often and be less painful if you keep taking Decryst every day.</p><p>Your doctor will often prescribe other medicines, if they are needed, to help prevent or treat the symptoms of flares (such as pain and swelling in a joint).</p><p>In patients with very high urate levels (e.g. those undergoing cancer chemotherapy), treatment with uric acid-lowering medicines could lead to the build-up of xanthine in the urinary tract, with possible stones, even though this has not been observed in patients being treated with febuxostat for Tumor Lysis Syndrome.</p><p>Your doctor may ask you to have blood tests to check that your liver is working normally.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Do not give this medicine to children under the age of 18 because the safety and efficacy have not been established.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Decryst</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p>It is especially important to tell your doctor or pharmacist if you are taking medicines containing any of the following substances as they may interact with Decryst and your doctor may wish to consider necessary measures:</p><p>&middot;&nbsp;&nbsp;Mercaptopurine (used to treat cancer)</p><p>&middot;&nbsp;&nbsp;Azathioprine (used to reduce immune response)</p><p>&middot;&nbsp;&nbsp;Theophylline (used to treat asthma)</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding </strong></p><p>It is not known if febuxostat may harm your unborn child. Febuxostat should not be used during pregnancy. It is not known if febuxostat may pass into human breast milk. You should not use febuxostat if you are breast feeding, or if you are planning to breastfeed.&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>Be aware that you may experience dizziness, sleepiness, blurred vision and numbness or tingling sensation during treatment and should not drive or operate machines if affected.</p><p>&nbsp;</p><p><strong>Decryst contains lactose monohydrate and sodium</strong></p><p>Decryst contains lactose monohydrate. Each film-coated tablet of 40 mg and 80 mg contains 90.125 mg or 180.25 mg lactose monohydrate; respectively. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p>Decryst contains sodium. Each film-coated tablet of 40 mg and 80 mg contains 1.8785 mg or 3.757 mg sodium; respectively. This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&middot;&nbsp;&nbsp;The usual dose is one tablet daily.</p><p>&middot;&nbsp;&nbsp;The tablets should be taken by mouth and can be taken with or without food.</p><p>&nbsp;</p><p><em>Gout </em></p><p>Febuxostat is available as either an 40 mg, 80 mg tablet or a 120 mg tablet. Your doctor will have prescribed the strength most suitable for you. &nbsp;</p><p>Continue to take Decryst every day even when you are not experiencing gout flare or attack.</p><p><em>Prevention and treatment of high uric acid levels in patients undergoing cancer chemotherapy </em></p><p>Febuxostat is available as a 120 mg tablet.</p><p>Start taking febuxostat two days before chemotherapy and continue its use according to your doctor&rsquo;s advice. Usually treatment is short-term.</p><p><strong>&nbsp;</strong></p><p><strong>If you take more Decryst than you should</strong></p><p>In the event of an accidental overdose ask your doctor what to do, or contact your nearest accident and emergency department.</p><p>&nbsp;</p><p><strong>If you forget to take Decryst</strong></p><p>If you miss a dose of Decryst take it as soon as you remember unless it is almost time for your next dose, in which case miss out the forgotten dose and take your next dose at the normal time. Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop taking Decryst</strong></p><p>Do not stop taking Decryst without the advice of your doctor even if you feel better. If you stop taking Decryst your uric acid levels may begin to rise and your symptoms may worsen due to the formation of new crystals of urate in and around your joints and kidneys.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Stop taking this medicine and contact your doctor immediately or go to an emergency department nearby if the following rare (may affect up to 1 in 1,000 people) side effects occur, because a serious allergic reaction might follow:</p><p>&middot;&nbsp;&nbsp;Anaphylactic reactions, drug hypersensitivity (see also section 2 &ldquo;Warnings and precautions&rdquo;)</p><p>&middot;&nbsp;&nbsp;Potentially life-threatening skin rashes characterized by formation of blisters and shedding of the skin and inner surfaces of body cavities, e.g. mouth and genitals, painful ulcers in the mouth and/or genital areas, accompanied by fever, sore throat and fatigue (Stevens- Johnson Syndrome/Toxic Epidermal Necrolysis), or by enlarged lymph nodes, liver enlargement, hepatitis (up to liver failure), raising of the white-cells count in the blood (drug reaction with eosinophilia and systemic symptoms-DRESS) (see section 2)</p><p>&middot;&nbsp;&nbsp;Generalised skin rashes</p><p>&nbsp;</p><p><strong>&nbsp;The common side effects (may affect up to 1 in 10 people) are:</strong></p><p>&middot;&nbsp;&nbsp;Abnormal liver test results</p><p>&middot;&nbsp;&nbsp;Diarrhoea</p><p>&middot;&nbsp;&nbsp;Headache</p><p>&middot;&nbsp;&nbsp;Rash (including various types of rash, please see below under &ldquo;uncommon&rdquo; and &ldquo;rare&rdquo; sections)</p><p>&middot;&nbsp;&nbsp;Nausea</p><p>&middot;&nbsp;&nbsp;Increase in gout symptoms</p><p>&middot;&nbsp;&nbsp;Localised swelling due to retention of fluids in tissues (oedema)</p><p>&nbsp;</p><p><strong><em>Other side effects which are not mentioned above are listed below.</em></strong></p><p>&nbsp;</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people) are:</strong></p><p>&middot;&nbsp;&nbsp;Decreased appetite, change in blood sugar levels (diabetes) of which a symptom may be excessive thirst, increased blood fat levels, weight increase</p><p>&middot;&nbsp;&nbsp;Loss of sex drive</p><p>&middot;&nbsp;&nbsp;Difficulty in sleeping, sleepiness</p><p>&middot; Dizziness, numbness, tingling, reduced or altered sensation (hypoaesthesia, hemiparesis or paraesthesia), altered sense of taste, diminished sense of smell (hyposmia)</p><p>&middot;&nbsp;&nbsp;Abnormal ECG heart tracing, irregular or rapid heartbeats, feeling your heart beat (palpitation)</p><p>&middot;&nbsp;Hot flushes or flushing (e.g. redness of the face or neck), increased blood pressure, bleeding (hemorrhage, seen only in patients taking chemotherapy for blood disorders)</p><p>&middot;&nbsp;Cough, shortness of breath, chest discomfort or pain, inflammation of nasal passage and/or throat (upper respiratory tract infection), bronchitis</p><p>&middot;&nbsp;Dry mouth, abdominal pain/discomfort or wind, heartburn/indigestion, constipation, more frequent passing of stools, vomiting, stomach discomfort</p><p>&middot;&nbsp;Itching, hives, skin inflammation, skin discoloration, small red or purple spots on the skin, small, flat red spots on the skin, flat, red area on the skin that is covered with small confluent bumps, rash, areas of redness and spots on the skin, other type of skin conditions</p><p>&middot;&nbsp;Muscle cramp, muscle weakness, pain/ache in muscles/joints, bursitis or arthritis (inflammation of joints usually accompanied by pain, swelling and/or stiffness), pain in extremity, back pain, muscle spasm</p><p>&middot;&nbsp;&nbsp;Blood in the urine, abnormal frequent urination, abnormal urine tests (increased level of proteins in the urine), a reduction in the ability of the kidneys to function properly</p><p>&middot;&nbsp;&nbsp;Fatigue, chest pain, chest discomfort</p><p>&middot;&nbsp;&nbsp;Stones in the gallbladder or in bile ducts (cholelithiasis)</p><p>&middot;&nbsp;&nbsp;Increase in blood thyroid stimulating hormone (TSH) level</p><p>&middot;&nbsp;&nbsp;Changes in blood chemistry or amount of blood cells or platelets (abnormal blood test results)</p><p>&middot;&nbsp;&nbsp;Kidney stones</p><p>&middot;&nbsp;&nbsp;Erectile difficulties</p><p>&nbsp;</p><p><strong>Rare side effects (may affect up to 1 in 1,000 people) are:</strong></p><p>&middot;&nbsp;Muscle damage, a condition which on rare occasions can be serious. It may cause muscle problems and particularly, if at the same time, you feel unwell or have a high temperature it may be caused by an abnormal muscle breakdown. Contact your doctor immediately if you experience muscle pain, tenderness or weakness</p><p>&middot;&nbsp;&nbsp;Severe swelling of the deeper layers of the skin, especially around the lips, eyes, genitals, hands, feet or tongue, with possible sudden difficult breathing</p><p>&middot; High fever in combination with measles-like skin rash, enlarged lymph nodes, liver enlargement, hepatitis (up to liver failure), raising of the white-cells count in the blood (leukocytosis, with or without eosinophilia)</p><p>&middot;&nbsp;&nbsp;Reddening of the skin (erythema), rash in various types (e.g. itchy, with white spots, with blisters, with blisters containing pus, with shedding of the skin, measles-like rash), widespread erythema, necrosis, and bullous detachment of the epidermis and mucous membranes, resulting in exfoliation and possible sepsis (Stevens-Johnson Syndrome/Toxic epidermal necrolysis)</p><p>&middot;&nbsp;&nbsp;Nervousness</p><p>&middot;&nbsp;&nbsp;Feeling thirsty</p><p>&middot;&nbsp;&nbsp;Ringing in the ears</p><p>&middot;&nbsp;&nbsp;Blurred vision, change in vision</p><p>&middot;&nbsp;&nbsp;Hair loss</p><p>&middot;&nbsp;&nbsp;Mouth ulceration</p><p>&middot;&nbsp;&nbsp;Inflammation of the pancreas: common symptoms are abdominal pain, nausea and vomiting</p><p>&middot;&nbsp;&nbsp;Increased sweating</p><p>&middot;&nbsp;&nbsp;Weight decrease, increased appetite, uncontrolled loss of appetite (anorexia)</p><p>&middot;&nbsp;&nbsp;Muscle and/or joint stiffness</p><p>&middot;&nbsp;&nbsp;Abnormally low blood cell counts (white or red blood cells or platelets)</p><p>&middot;&nbsp;&nbsp;Urgent need to urinate</p><p>&middot;&nbsp;&nbsp;Changes or decrease in urine amount due to inflammation in the kidneys (tubulointerstitial nephritis)</p><p>&middot;&nbsp;&nbsp;Inflammation of the liver (hepatitis)</p><p>&middot;&nbsp;&nbsp;Yellowing of the skin (jaundice)</p><p>&middot;&nbsp;&nbsp; Liver damage</p><p>&middot;&nbsp;&nbsp;Increased level of creatine phosphokinase in blood (an indicator of muscle damage)</p><p>&middot;&nbsp;&nbsp;Sudden cardiac death</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not store above 30&deg;C.</p><p>Store in the original package.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">The active substance is febuxostat.</p><p style="text-align:justify">Each film-coated tablet of Decryst 40 mg Film-coated Tablets contains 40 mg febuxostat.</p><p style="text-align:justify">Each film-coated tablet of Decryst 80 mg Film-coated Tablets contains 80 mg febuxostat.</p><p style="text-align:justify">The other ingredients are: <em>Tablet core:</em> lactose monohydrate, microcrystalline cellulose, hypromellose, sodium lauryl sulfate, croscarmellose sodium, colloidal silicon dioxide and magnesium stearate. <em>Tablet coat:</em> Opadry Green.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Decryst 40 mg Film-coated Tablets are green round coated tablets embossed with “FT” on one side and “40” on the other side in PVC/PE/PVDC with aluminum foil blisters.

Decryst 80 mg Film-coated Tablets are green round coated tablets embossed with “FT” on one side and “80” on the other side in PVC/PE/PVDC with aluminum foil blisters.

Pack size: 30 Film-coated tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. BOX 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 03/2021; version number SA1.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">تحتوي أقراص ديكريست على المادة الفعّالة فيبوكسوستات وتستخدم لعلاج النقرس، الذي يرتبط بزيادة مادة كيميائية تسمى حمض اليوريك (اليورات) في الجسم. لدى بعض الأشخاص، تتراكم كمية حمض اليوريك في الدم وقد تصبح مرتفعة جداً بحيث لا تبقى قابلة للذوبان. عندما يحدث ذلك، قد تتكون بلورات اليورات داخل وحول المفاصل والكليتين. يمكن أن تسبب هذه البلورات ألم مفاجئ وشديد، احمرار، سخونة وتورم في المفصل (يعرف بنوبة النقرس). إذا تُركت دون معالجة، قد تتشكل رواسب أكبر تسمى تُوفِيّ داخل المفاصل وحولها. قد تتسبب هذه التُوفِيّات في تلف المفاصل والعظام.</p><p dir="RTL">يعمل ديكريست عن طريق خفض مستويات حمض اليوريك. يعمل الحفاظ على مستويات منخفضة من حمض اليوريك عن طريق تناول فيبوكسوستات مرة واحدة كل يوم على توقف تراكم البلورات، ومع مرور الوقت يقلل من الأعراض. الحفاظ على مستويات حمض اليوريك منخفضة بما فيه الكفاية لفترة طويلة يمكن أيضاً أن يقلّص من التُوفِيّ.</p><p dir="RTL">تستخدم أقراص فيبوكسوستات 120 ملغم أيضاً لعلاج ومنع ارتفاع مستويات حمض اليوريك في الدم والتي قد تحدث عندما تبدأ في تلقي العلاج الكيميائي لسرطان الدم.</p><p dir="RTL">عندما يتم إعطاء العلاج الكيميائي، يتم تدمير الخلايا السرطانية، وتزيد مستويات حمض اليوريك في الدم وفقاً لذلك، ما لم يتم منع تكوين حمض اليوريك.</p><p dir="RTL">يستخدم ديكريست لدى البالغين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول ديكريست </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;إذا كان لديك حساسية لفيبوكسوستات أو لأي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الاحتياطات والتحذيرات</strong></p><p dir="RTL">تحدث إلى طبيبك قبل تناول ديكريست:</p><p dir="RTL">&bull;&nbsp;إذا كان لديك أو سبق وعانيت من قصور في القلب، مشاكل في القلب أو سكتة</p><p dir="RTL">&bull;&nbsp;إذا كان لديك أو سبق وعانيت من مرض في الكلى و/أو رد فعل تحسسي خطير لألوبيورينول (دواء يستخدم لعلاج النقرس)</p><p dir="RTL">&bull;&nbsp;إذا كان لديك أو سبق وعانيت من مرض في الكبد أو اضطرابات في فحوصات وظائف الكبد</p><p dir="RTL">&bull;&nbsp;&nbsp;إذا كنت تتعالج من ارتفاع مستويات حمض اليوريك كنتيجة لمتلازمة لش-نيهان (حالة وراثية نادرة يوجد فيها الكثير من حمض اليوريك في الدم)</p><p dir="RTL">&bull;&nbsp;&nbsp;إذا كان لديك مشاكل في الغدة الدرقية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعاني من الحساسية تجاه فيبوكسوستات، فتوقف عن تناول هذا الدواء (انظر أيضاً القسم 4). قد تكون الأعراض المحتملة لردود الفعل التحسسية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي بما في ذلك الأشكال الشديدة (مثل: البثور، العقيدات، الطفح الجلدي المقشّر المثير للحكة)، حكة</p><p dir="RTL">&bull;&nbsp;&nbsp;تورم الأطراف أو الوجه</p><p dir="RTL">&bull;&nbsp;&nbsp;صعوبات في التنفس</p><p dir="RTL">&bull;&nbsp;&nbsp;حمّى مع تضخم الغدد الليمفاوية</p><p dir="RTL">&bull;&nbsp;&nbsp;ولكن أيضاً حالات تحسسية خطيرة مهددة للحياة مع توقف القلب والدورة الدموية.</p><p dir="RTL">قد يقرر طبيبك التوقف الدائم عن العلاج باستخدام ديكريست.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كانت هناك تقارير نادرة عن طفح جلدي محتمل مهدّد للحياة (متلازمة ستيفنز-جونسون) باستخدام فيبوكسوستات، والذي يظهر في البداية كبقع حمراء تشبه المحور أو لطخات دائرية غالباً مع وجود بثور مركزية على الجذع. قد يشمل أيضاً تقرحات في الفم، الحلق، الأنف، الأعضاء التناسلية والتهاب الملتحمة (احمرار وتورم العينين). قد يتطور الطفح الجلدي إلى تقرحات أو تقشّر منتشر على الجلد.</p><p dir="RTL">إذا أصبت بمتلازمة ستيفنز-جونسون باستخدام فيبوكسوستات، فلا يجب إعادة إعطائك ديكريست في أي وقت. إذا أصبت بطفح جلدي أو هذه الأعراض الجلدية، فاطلب نصيحة فورية من الطبيب وأخبره أنك تتناول هذا الدواء.</p><p dir="RTL">إذا كنت تعاني من نوبة النقرس في الوقت الحالي (ظهور مفاجئ لألم شديد، ألم عند الضغط، احمرار، سخونة وتورم في المفصل)، انتظر حتى تهدأ نوبة النقرس قبل بدء العلاج بديكريست لأول مرة.</p><p dir="RTL">بالنسبة لبعض الأشخاص، قد تتوهج نوبات النقرس عند بدء بعض الأدوية التي تتحكم في مستويات حمض اليوريك. لا يصاب الجميع بتوهج، ولكن يمكن أن يحدث لديك توهج حتى إذا كنت تتناول ديكريست، وخاصة خلال الأسابيع أو الأشهر الأولى من العلاج. من المهم الاستمرار في تناول ديكريست حتى إذا كان لديك توهج، لأن ديكريست لا يزال يعمل على التقليل من حمض اليوريك. مع مرور الوقت، ستحدث توهجات النقرس بشكل أقل وستكون أقل ألماً إذا واصلت في تناول ديكريست يومياً.</p><p dir="RTL">غالباً ما يصف طبيبك أدوية أخرى، إذا لزم الأمر، للمساعدة في منع أو علاج أعراض النوبات التوهجية (مثل الألم والتورم في المفصل).</p><p dir="RTL">لدى المرضى الذين يعانون من مستويات عالية من اليورات (مثل: أولئك الذين يخضعون للعلاج الكيميائي للسرطان)، يمكن أن يؤدي العلاج بالأدوية التي تعمل على تخفيض حمض اليوريك إلى تراكم الزانثين في المسالك البولية، مع وجود حصوات محتملة، على الرغم من عدم ملاحظة ذلك لدى المرضى الذين يتم علاجهم بفيبوكسوستات لمتلازمة انحلال الورم.</p><p dir="RTL">قد يطلب منك طبيبك إجراء فحوصات للدم للتحقق من أن الكبد يعمل بشكل طبيعي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">لا تعطي هذا الدواء للأطفال تحت سن 18 لأنه لم تثبت السلامة والفعالية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وديكريست</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، تناولت مؤخراً أو قد تتناول أي أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها بدون وصفة طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من المهم بشكل خاص إخبار طبيبك أو الصيدلي إذا كنت تتناول أدوية تحتوي على أي من المواد التالية لأنها قد تتفاعل مع ديكريست وقد يرغب طبيبك في التفكير في التدابير اللازمة:</p><p dir="RTL">&bull; ميركابتوبيورين (يستخدم لعلاج السرطان)</p><p dir="RTL">&bull; آزوثيوبرين (يستخدم لتقليل الاستجابة المناعية)</p><p dir="RTL">&bull; ثيوفيلين (يستخدم لعلاج الربو)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">من غير المعروف ما إذا كان فيبوكسوستات قد يضر بجنينك. لا ينبغي استخدام فيبوكسوستات أثناء الحمل. من غير المعروف ما إذا كان فيبوكسوستات قد ينتقل إلى حليب الثدي البشري. يجب عدم استخدام فيبوكسوستات إذا كنت ترضعين طفلك رضاعة طبيعية، أو إذا كنت تخططين للرضاعة الطبيعية.</p><p dir="RTL">إذا كنت حاملاً أو مرضعة، تعتقدين بأنك قد تكونين حاملاً أو تخططين لإنجاب طفل، اسألي طبيبك أو الصيدلي للحصول على المشورة قبل تناول هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">كن على علم أنك قد تعاني أثناء العلاج من الدوخة، النعاس، عدم وضوح في الرؤية والخدران أو الإحساس بالوخز ويجب ألا تقود أو تقم بتشغيل الآلات إذا حصل معك ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي ديكريست على </strong><strong>ال</strong><strong>لاكتوز أحادي الماء</strong><strong> والصوديوم </strong></p><p dir="RTL">يحتوي ديكريست على اللاكتوز أحادي الماء. يحتوي كل قرص من 40 ملغم و80 ملغم على 90.125 ملغم أو 180.25 ملغم لاكتوز أحادي الماء؛ على التوالي. إذا أخبرك طبيبك أن لديك عدم تحمل لبعض السكريات، اتصل بطبيبك قبل تناول هذا المستحضر الدوائي.</p><p>يحتوي ديكريست على الصوديوم. يحتوي كل قرص مغطى بطبقة رقيقة من 40 ملغم و80 ملغم على 1.8785 ملغم أو 3.757 ملغم صوديوم؛ على التوالي. يحتوي هذا الدواء على أقل من 1 ملمول صوديوم (23 ملغم) لكل قرص مغطى بطبقة رقيقة، وبذلك يمكن اعتباره &rsquo;خالٍ من الصوديوم&lsquo; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدواء دائماً كما أخبرك طبيبك تماماً. استشر طبيبك أو الصيدلي إذا لم تكن متأكداً.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull; الجرعة المعتادة هي قرص واحد يومياً.</p><p dir="RTL">&bull; يجب تناول الأقراص عن طريق الفم ويمكن تناولها مع الطعام أو بدونه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>النقرس</em></p><p dir="RTL">يتوفر فيبوكسوستات إما على شكل قرص من 40 ملغم، 80 ملغم أو 120 ملغم. سيصف لك طبيبك الجرعة الأكثر ملاءمة لك.</p><p dir="RTL">استمر في تناول ديكريست كل يوم حتى عندما لا تتعرض لتوهج أو لنوبة النقرس.</p><p dir="RTL"><em>الوقاية والعلاج من ارتفاع مستويات حمض اليوريك لدى المرضى الذين يخضعون للعلاج الكيميائي للسرطان</em></p><p dir="RTL">يتوفر فيبوكسوستات على شكل أقراص من 120 ملغم.</p><p dir="RTL">ابدأ بتناول فيبوكسوستات قبل يومين من العلاج الكيميائي واستمر في استخدامه وفقاً لنصيحة طبيبك. عادة ما يكون العلاج قصير المدى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت جرعة زائدة من ديكريست</strong></p><p dir="RTL">في حالة الجرعة الزائدة العرضية، اسأل طبيبك عمّا يجب فعله، أو اتصل بأقرب قسم للحوادث والطوارئ.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت تناول ديكريست</strong></p><p dir="RTL">إذا نسيت تناول جرعة من ديكريست، تناولها فور تذكرها ما لم يكن قد حان الوقت للجرعة التالية، وفي هذه الحالة تجاهل الجرعة المنسية وتناول الجرعة التالية في وقتها المعتاد. لا تقم بتناول جرعة مضاعفة للتعويض عن الجرعة المنسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول ديكريست</strong></p><p dir="RTL">لا تتوقف عن تناول ديكريست دون نصيحة طبيبك حتى لو كنت تشعر بتحسن. إذا توقفت عن تناول ديكريست، فقد تبدأ مستويات حمض اليوريك في الارتفاع وقد تتفاقم أعراضك بسبب تكوين بلورات جديدة من اليورات داخل وحول المفاصل والكليتين.</p><p dir="RTL">إذا كان لديك أي أسئلة إضافية حول استخدام هذا الدواء، يرجى استشارة الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبيةً، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL">توقف عن تناول هذا الدواء واتصل بطبيبك على الفور أو اذهب إلى أقرب قسم طوارئ إذا حدثت الآثار الجانبية النادرة التالية (قد تؤثر على ما يصل إلى 1 من 1,000 شخص)، لأنه قد يتبعها رد فعل تحسسي خطير:</p><p dir="RTL">&bull;&nbsp;ردود الفعل التأقيّة، فرط الحساسية للأدوية (انظر أيضاً القسم 2 &quot;الاحتياطات والتحذيرات&quot;)</p><p dir="RTL">&bull;&nbsp;طفح جلدي محتمل مهددّ للحياة يتميز بتشكيل بثور وتقشّر الجلد والأسطح الداخلية لتجاويف الجسم، مثل: الفم والأعضاء التناسلية، تقرحات مؤلمة في الفم و/أو المناطق التناسلية، مصحوبة بالحمّى، التهاب الحلق والتعب (متلازمة&nbsp;ستيفنز-جونسون/تقشّر الأنسجة المتموّتة البشرويّة التسمميّ)، أو تضخم الغدد الليمفاوية، تضخم الكبد، التهاب الكبد (حتى فشل الكبد)، ارتفاع في عدد الخلايا البيضاء في الدم (رد فعل دوائي مع فرط اليوزينيات والأعراض الجهازية) (انظر القسم 2)</p><p dir="RTL">&bull;&nbsp;طفح جلدي معممّ</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشائعة</strong> (قد تؤثر على ما يصل إلى 1 من 10 أشخاص) وهي:</p><p dir="RTL">&bull;&nbsp;نتائج غير طبيعية في فحوصات الكبد</p><p dir="RTL">&bull;&nbsp;إسهال</p><p dir="RTL">&bull;&nbsp;صداع</p><p dir="RTL">&bull;&nbsp;طفح جلدي (بما في ذلك أنواع مختلفة من الطفح الجلدي، يرجى الاطلاع تحت الأقسام أدناه &quot;غير شائع&quot; و&quot;نادر&quot;)</p><p dir="RTL">&bull;&nbsp;غثيان</p><p dir="RTL">&bull;&nbsp;زيادة في أعراض النقرس</p><p dir="RTL">&bull;&nbsp;تورم موضعي بسبب احتباس السوائل في الأنسجة (الوذمة)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>الآثار الجانبية الأخرى غير المذكورة في الأعلى مدرجة أدناه</em></strong><strong><em>.</em></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة</strong> <strong>(قد تؤثر على ما يصل إلى 1 من 100 شخص) وهي</strong><strong>:</strong></p><p dir="RTL">&bull;&nbsp;قلة الشهية، التغير في مستويات السكر في الدم (السكري) والذي قد تكون من أعراضه العطش الشديد، زيادة مستويات الدهون في الدم، زيادة الوزن</p><p dir="RTL">&bull;&nbsp;فقدان الدافع الجنسي</p><p dir="RTL">&bull;&nbsp;صعوبة في النوم، النعاس</p><p dir="RTL">&bull;&nbsp;دوخة، خدران، وخز، ضعف أو تغيّر في الإحساس (نقص الإحساس، شلل نصفي أو مذل)، تغيّر حاسة التذوق، ضعف في حاسة الشم (نقص حاسة الشم)</p><p dir="RTL">&bull;&nbsp;مُرتسم غير طبيعي لمخطط كهربية القلب، عدم انتظام نبضات القلب أو عدم انتظامها، الشعور بنبض القلب (الخفقان)</p><p dir="RTL">&bull;&nbsp;التورّد (مثل: احمرار الوجه أو الرقبة)، زيادة في ضغط الدم، نزيف (نزيف، يظهر فقط لدى المرضى الذين يتلقون العلاج الكيميائي لاضطرابات الدم)</p><p dir="RTL">&bull;&nbsp;السعال، ضيق في التنفس، عدم الراحة أو الشعور بألم في الصدر، التهاب في مجرى الأنف و/أو الحلق (عدوى الجهاز التنفسي العلوي)، التهاب القصبات</p><p dir="RTL">&bull;&nbsp;جفاف في الفم، آلام في البطن/عدم الراحة أو خروج الريح، حرقة المعدة/عسر الهضم، إمساك، تكرر خروج البراز، تقيؤ، انزعاج معدي</p><p dir="RTL">&bull;&nbsp;حكة، شرى، التهاب الجلد، تغيّر لون الجلد، بقع حمراء أو أرجوانية صغيرة على الجلد، بقع حمراء مسطحة صغيرة على الجلد، منطقة حمراء مسطحة على الجلد مغطاة بنتوءات صغيرة متجمعة، طفح جلدي، مناطق احمرار وبقع على الجلد، نوع آخر من الأمراض الجلدية</p><p dir="RTL">&bull;&nbsp;تشنج العضلات، ضعف العضلات، ألم في العضلات/المفاصل، التهاب الجِراب<strong> </strong>أو التهاب المفاصل (التهاب المفاصل مصحوب عادةً بألم، تورم و/أو تصلب)، ألم في الأطراف، آلام في الظهر، تشنج عضلي</p><p dir="RTL">&bull; دم في البول، تبول متكرر غير طبيعي، فحوصات غير طبيعية في البول (زيادة مستوى البروتينات في البول)، انخفاض في قدرة الكلى على العمل بشكل صحيح</p><p dir="RTL">&bull; تعب، ألم في الصدر، عدم الراحة في الصدر</p><p dir="RTL">&bull; حصى في المرارة أو في القنوات الصفراوية (تحصي صفراوي)</p><p dir="RTL">&bull;&nbsp;زيادة مستوى الهرمون المحفز للغدة الدرقية في الدم</p><p dir="RTL">&bull;&nbsp;تغيرات في كيمياء الدم أو في كمية خلايا الدم أو في الصفائح الدموية (نتائج غير طبيعية في فحوصات الدم)</p><p dir="RTL">&bull;&nbsp;حصى الكلى</p><p dir="RTL">&bull;&nbsp;صعوبات في الانتصاب</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية النادرة (قد تؤثر على ما يصل إلى 1 من 1,000 شخص) وهي:</strong></p><p dir="RTL">&bull;&nbsp;تلف في العضلات، وهي حالة قد تكون خطيرة في حالات نادرة. قد تسبب مشاكل في العضلات وعلى وجه الخصوص، إذا شعرت في نفس الوقت بتوعك أو كان لديك ارتفاع في درجة الحرارة فقد يكون ذلك بسبب انحلال غير طبيعي للعضلات. اتصل بطبيبك على الفور إذا كنت تعاني من آلام في العضلات، أو ألم عند الضغط أو ضعف</p><p dir="RTL">&bull;&nbsp;تورم شديد في الطبقات العميقة من الجلد، خاصة حول الشفتين، العينين، الأعضاء التناسلية، اليدين، القدمين أو اللسان، مع احتمال مفاجئ بوجود صعوبة التنفس</p><p dir="RTL">&bull;&nbsp;ارتفاع في درجة الحرارة بالتزامن مع وجود طفح جلدي يشبه الحصبة، تضخم الغدد الليمفاوية، تضخم الكبد، التهاب الكبد (حتى فشل الكبد)، زيادة عدد الخلايا البيضاء في الدم (زيادة عدد الكريات البيضاء، مع أو بدون فرط اليوزينيات)</p><p dir="RTL">&bull;&nbsp;احمرار الجلد (حمامى)، طفح جلدي في أنواع مختلفة (مثل: حكة، مع بقع بيضاء، مع بثور، مع بثور تحتوي على قيح، مع تقشّر الجلد، مع طفح شبيه بالحصبة)، حمامى منتشرة، نخر وانفصال فقاعي للبشرة والأغشية المخاطية، ممّا يؤدي إلى تقشير وإنتان محتمل (متلازمة&nbsp;ستيفنز-جونسون/تقشّر الأنسجة المتموّتة البشرويّة التسمميّ)</p><p dir="RTL">&bull;&nbsp;العصبية</p><p dir="RTL">&bull;&nbsp;الشعور بالعطش</p><p dir="RTL">&bull;&nbsp;طنين في الأذنين</p><p dir="RTL">&bull;&nbsp;عدم وضوح في الرؤية، تغّير في الرؤية</p><p dir="RTL">&bull;&nbsp;&nbsp;تساقط الشعر</p><p dir="RTL">&bull;&nbsp;تقرّح الفم</p><p dir="RTL">&bull;&nbsp;التهاب البنكرياس: الأعراض الشائعة هي آلام البطن، الغثيان والقيء</p><p dir="RTL">&bull;&nbsp;زيادة التعرّق</p><p dir="RTL">&bull;&nbsp;نقصان في الوزن، زيادة الشهية، فقدان شهية غيرمتحكم به (فقدان الشهية)</p><p dir="RTL">&bull;&nbsp;تصلب العضلات و/أو المفاصل</p><p dir="RTL">&bull;&nbsp;انخفاض عدد خلايا الدم بشكل غير طبيعي (خلايا الدم البيضاء أو الحمراء أو الصفائح الدموية)</p><p dir="RTL">&bull;&nbsp; الحاجة الملّحة للتبول</p><p dir="RTL">&bull;&nbsp;تغيّرات أو نقصان في كمية البول بسبب التهاب في الكلى (التهاب الكلية الأنبوبي الخلالي)</p><p dir="RTL">&bull;&nbsp;التهاب الكبد</p><p dir="RTL">&bull;&nbsp;اصفرار في الجلد (اليرقان)</p><p dir="RTL">&bull;&nbsp;تلف الكبد</p><p dir="RTL">&bull;&nbsp;زيادة مستوى كرياتين الفوسفوكيناز في الدم (مؤشر على تلف العضلات)</p><p dir="RTL">&bull;&nbsp;الموت القلبي المفاجئ</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL" style="text-align:justify">لا يحفظ عند درجة حرارة أعلى من 30&deg; مئوية.</p><p dir="RTL" style="text-align:justify">يحفظ داخل العبوة الأصلية.</p><p dir="RTL" style="text-align:justify">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد&rdquo;EXP&rdquo; . يشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL" style="text-align:justify">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p style="text-align:justify">لا تتخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify"><strong>ما هي محتويات ديكريست</strong></p><p dir="RTL" style="text-align:justify">المادة الفعّالة هي فيبوكسوستات.</p><p dir="RTL" style="text-align:justify">يحتوي كل قرص مغطى بطبقة رقيقة من ديكريست 40 ملغم أقراص مغطاة بطبقة رقيقة على 40 ملغم فيبوكسوستات.</p><p dir="RTL" style="text-align:justify">يحتوي كل قرص مغطى بطبقة رقيقة من ديكريست 80 ملغم أقراص مغطاة بطبقة رقيقة على 80 ملغم فيبوكسوستات.</p><p dir="RTL" style="text-align:justify">المواد الأخرى المستخدمة في التركيبة التصنيعية هي: <em>لب القرص</em><em>: </em>لاكتوز أحادي الماء، سيلليلوز بلوري مكروي، هيبروميللوز، كبريتات لوريل الصوديوم، كروسكارمیللوز الصودیوم، ثاني أكسيد السيليكون الغروي وستيرات المغنيسيوم. <em>غلاف القرص</em><em>:</em> أوبادري أخضر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify">ديكريست 40 ملغم أقراص مغطاة بطبقة رقيقة هي عبارة عن أقراص لونها أخضر دائرية الشكل مغطاة بطبقة رقيقة منقوش عليها &ldquo;FT&rdquo; على جهة واحدة و&ldquo;40&rdquo; على الجهة الأخرى في أشرطة من كلوريد متعدد الڤينيل/متعدد الإيثيلين/متعدد كلوريد الڤينيليدين مع رقائق من الألومينيوم.</p><p dir="RTL" style="text-align:justify">ديكريست 80 ملغم أقراص مغطاة بطبقة رقيقة هي عبارة عن أقراص لونها أخضر دائرية الشكل مغطاة بطبقة رقيقة منقوش عليها &ldquo;FT&rdquo; على جهة واحدة و &rdquo;80&rdquo;على الجهة الأخرى في أشرطة من كلوريد متعدد الڤينيل/متعدد الإيثيلين/متعدد كلوريد الڤينيليدين مع رقائق من الألومينيوم.</p><p dir="RTL" style="text-align:justify">حجم العبوة: 30 قرص مغطى بطبقة رقيقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية</p><p dir="RTL" style="text-align:justify">هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 03/2021؛ رقم النسخة SA1.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Decryst 40 mg Film-coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 40 mg febuxostat.

Excipients with known effect: Lactose monohydrate and sodium.

Each film-coated tablet contains 90.125 mg lactose monohydrate.

Each film-coated tablet contains 1.8785 mg sodium.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated Tablets.

Green round coated tablets embossed with “FT” on one side and “40” on the other side. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Decryst is indicated for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).</p><p>Febuxostat 120 mg is indicated for the prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumor Lysis Syndrome (TLS).</p><p>Decryst is indicated in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><em>Gout:</em></p><p>The recommended oral dose of febuxostat is 80 mg once daily without regard to food. If serum uric acid is &gt; 6 mg/dL (357 &micro;mol/L) after 2-4 weeks, febuxostat 120 mg once daily may be considered.</p><p>Decryst works sufficiently quickly to allow retesting of the serum uric acid after 2 weeks. The therapeutic target is to decrease and maintain serum uric acid below 6 mg/dL (357 &mu;mol/L).</p><p>Gout flare prophylaxis of at least 6 months is recommended (see section 4.4).</p><p><em>&nbsp;</em></p><p><em>Tumor Lysis Syndrome</em>:</p><p>The recommended oral dose of febuxostat is 120 mg once daily without regard to food.</p><p>Febuxostat should be started two days before the beginning of cytotoxic therapy and continued for a minimum of 7 days; however treatment may be prolonged up to 9 days according to chemotherapy duration as per clinical judgment.</p><p><em>&nbsp;</em></p><p><em>Elderly</em></p><p>No dose adjustment is required in the elderly (see section 5.2).</p><p><em>&nbsp;</em></p><p><em>Renal impairment</em></p><p>The efficacy and safety have not been fully evaluated in patients with severe renal impairment (creatinine clearance &lt;30 mL/min, see section 5.2).</p><p>No dose adjustment is necessary in patients with mild or moderate renal impairment.</p><p><em>&nbsp;</em></p><p><em>Hepatic impairment</em></p><p>The efficacy and safety of febuxostat has not been studied in patients with severe hepatic impairment (Child Pugh Class C).</p><p>Gout: The recommended dose in patients with mild hepatic impairment is 80 mg. Limited information is available in patients with moderate hepatic impairment.</p><p>Tumour Lysis Syndrome: in the pivotal Phase III trial (FLORENCE) only subjects with severe hepatic insufficiency were excluded from trial participation. No dose adjustment was required for enrolled patients on the basis of hepatic function.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and the efficacy of febuxostat in children aged below the age of 18 years have not been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Oral use</p><p>Decryst should be taken by mouth and can be taken with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 (see also section 4.8).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Cardio-vascular disorders</u></p><p><em>Treatment of chronic hyperuricaemia</em></p><p>Treatment with febuxostat in patients pre-existing major cardiovascular diseases (e.g. myocardial infarction, stroke or unstable angina) should be avoided, unless no other therapy options are appropriate.</p><p>A numerical greater incidence of investigator-reported cardiovascular APTC events (defined endpoints from the Anti-Platelet Trialists&#39; Collaboration (APTC) including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) was observed in the febuxostat total group compared to the allopurinol group in the APEX and FACT studies (1.3 vs. 0.3 events per 100 Patient Years (PYs)), but not in the CONFIRMS study (see section 5.1 for detailed characteristics of the studies). The incidence of investigator-reported cardiovascular APTC events in the combined Phase 3 studies (APEX, FACT and CONFIRMS studies) was 0.7 vs. 0.6 events per 100 PYs. In the long-term extension studies the incidences of investigator-reported APTC events were 1.2 and 0.6 events per 100 PYs for febuxostat and allopurinol, respectively. No statistically significant differences were found and no causal relationship with febuxostat was established. Identified risk factors among these patients were a medical history of atherosclerotic disease and/or myocardial infarction, or of congestive heart failure.</p><p>In the post registrational CARES trial (see section 5.1 for detailed characteristics of the study) the rate of MACE events was similar in febuxostat versus allopurinol treated patients (HR 1.03;95% CI 0.87-1.23), but a higher rate of cardiovascular deaths was observed (4.3% vs. 3.2% of patients; HR 1.34; 95% CI 1.03-1.73).</p><p>&nbsp;</p><p><em>Prevention and treatment of hyperuricaemia in patients at risk of TLS</em></p><p>Patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumor Lysis Syndrome treated with febuxostat should be under cardiac monitoring as clinically appropriate.</p><p>&nbsp;</p><p><u>Medicinal product allergy / hypersensitivity</u></p><p>Rare reports of serious allergic/hypersensitivity reactions, including life-threatening Stevens-Johnson Syndrome, Toxic epidermal necrolysis and acute anaphylactic reaction/shock, have been collected in the post-marketing experience. In most cases, these reactions occurred during the first month of therapy with febuxostat. Some, but not all of these patients reported renal impairment and/or previous hypersensitivity to allopurinol. Severe hypersensitivity reactions, including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) were associated with fever, haematological, renal or hepatic involvement in some cases.</p><p>Patients should be advised of the signs and symptoms and monitored closely for symptoms of allergic/hypersensitivity reactions (see section 4.8). Febuxostat treatment should be immediately stopped if serious allergic/hypersensitivity reactions, including Stevens-Johnson Syndrome, occur since early withdrawal is associated with a better prognosis. If patient has developed allergic/hypersensitivity reactions including Stevens-Johnson Syndrome and acute anaphylactic reaction/shock, febuxostat must not be re-started in this patient at any time.</p><p>&nbsp;</p><p><u>Acute gouty attacks (gout flare)</u></p><p>Febuxostat treatment should not be started until an acute attack of gout has completely subsided. Gout flares may occur during initiation of treatment due to changing serum uric acid levels resulting in mobilization of urate from tissue deposits (see sections 4.8 and 5.1). At treatment initiation with febuxostat flare prophylaxis for at least 6 months with an NSAID or colchicine is recommended (see section 4.2).</p><p>If a gout flare occurs during febuxostat treatment, it should not be discontinued. The gout flare should be managed concurrently as appropriate for the individual patient. Continuous treatment with febuxostat decreases frequency and intensity of gout flares.</p><p>&nbsp;</p><p><u>Xanthine deposition</u></p><p>In patients in whom the rate of urate formation is greatly increased (e.g. malignant disease and its treatment, Lesch-Nyhan syndrome) the absolute concentration of xanthine in urine could, in rare cases, rise sufficiently to allow deposition in the urinary tract. This has not been observed in the pivotal clinical study with febuxostat in the Tumor Lysis Syndrome. As there has been no experience with febuxostat, its use in patients with Lesch-Nyhan Syndrome is not recommended.</p><p>&nbsp;</p><p><u>Mercaptopurine/azathioprine</u></p><p>Febuxostat use is not recommended in patients concomitantly treated with mercaptopurine/azathioprine as inhibition of xanthine oxidase by febuxostat may cause increased plasma concentrations of mercaptopurine/azathioprine that could result in severe toxicity. No interaction studies have been performed in humans.</p><p>Where the combination cannot be avoided, a reduction of the dose of mercaptopurine/azathioprine is recommended. Based on modelling and simulation analysis of data from a pre-clinical study in rats, when coadministered with febuxostat, the dose of mercaptopurine/azathioprine should be reduced to the 20% or less of the previously prescribed dose in order to avoid possible haematological effects (see section 4.5 and 5.3).</p><p>The patients should be closely monitored and the dose of mercaptopurine/azathioprine should be subsequently adjusted based on the evaluation of the therapeutic response and the onset of eventual toxic effects.</p><p>&nbsp;</p><p><u>Organ transplant recipients</u></p><p>As there has been no experience in organ transplant recipients, the use of febuxostat in such patients is not recommended (see section 5.1).</p><p>&nbsp;</p><p><u>Theophylline</u></p><p>Co-administration of febuxostat 80 mg and theophylline 400mg single dose in healthy subjects showed absence of any pharmacokinetic interaction (see section 4.5).</p><p>Febuxostat 80 mg can be used in patients concomitantly treated with theophylline without risk of increasing theophylline plasma levels. No data is available for febuxostat 120 mg.</p><p>&nbsp;</p><p><u>Liver disorders</u></p><p>During the combined phase 3 clinical studies, mild liver function test abnormalities were observed in patients treated with febuxostat (5.0%). Liver function test is recommended prior to the initiation of therapy with febuxostat and periodically thereafter based on clinical judgment (see section 5.1).</p><p>&nbsp;</p><p><u>Thyroid disorders</u></p><p>Increased TSH values (&gt;5.5 &micro;IU/mL) were observed in patients on long-term treatment with febuxostat (5.5%) in the long term open label extension studies. Caution is required when febuxostat is used in patients with alteration of thyroid function (see section 5.1).</p><p>&nbsp;</p><p><u>Decryst contains lactose monohydrate and sodium</u></p><p>Decryst contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>Decryst contains sodium. This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Mercaptopurine/azathioprine</u></p><p>On the basis of the mechanism of action of febuxostat on XO inhibition concomitant use is not recommended. Inhibition of XO by febuxostat may cause increased plasma concentrations of these drugs leading to toxicity. Drug interaction studies of febuxostat with drugs (except theophylline) that are metabolized by XO have not been performed in humans.</p><p>Modelling and simulation analysis of data from a pre-clinical study in rats indicates that, in case of concomitant administration with febuxostat, the dose of mercaptopurine/azathioprine should be reduced to 20% or less of the previously prescribed dose (see section 4.4 and 5.3).</p><p>Drug interaction studies of febuxostat with other cytotoxic chemotherapy have not been conducted. In the Tumor Lysis Syndrome pivotal trial febuxostat 120 mg daily was administered to patients undergoing several chemotherapy regimens, including monoclonal antibodies. However, drug-drug and drug-disease interactions were not explored during this study. Therefore, possible interactions with any concomitantly administered cytotoxic drug cannot be ruled out.</p><p>&nbsp;</p><p><u>Rosiglitazone/CYP2C8 substrates</u></p><p>Febuxostat was shown to be a weak inhibitor of CYP2C8 in vitro. In a study in healthy subjects, coadministration of 120 mg febuxostat QD with a single 4 mg oral dose of rosiglitazone had no effect on the pharmacokinetics of rosiglitazone and its metabolite N-desmethyl rosiglitazone, indicating that febuxostat is not a CYP2C8 enzyme inhibitor in vivo. Thus, co-administration of febuxostat with rosiglitazone or other CYP2C8 substrates is not expected to require any dose adjustment for those compounds.</p><p>&nbsp;</p><p><u>Theophylline</u></p><p>An interaction study in healthy subjects has been performed with febuxostat to evaluate whether the inhibition of XO may cause an increase in the theophylline circulating levels as reported with other XO inhibitors. The results of the study showed that the co-administration of febuxostat 80 mg QD with theophylline 400 mg single dose has no effect on the pharmacokinetics or safety of theophylline. Therefore no special caution is advised when febuxostat 80 mg and theophylline are given concomitantly. No data is available for febuxostat 120 mg.</p><p>&nbsp;</p><p><u>Naproxen and other inhibitors of glucuronidation</u></p><p>Febuxostat metabolism depends on Uridine Glucuronosyl Transferase (UGT) enzymes. Medicinal products that inhibit glucuronidation, such as NSAIDs and probenecid, could in theory affect the elimination of febuxostat. In healthy subjects concomitant use of febuxostat and naproxen 250 mg twice daily was associated with an increase in febuxostat exposure (C<sub>max</sub>&nbsp;28%, AUC 41% and t<sub>1/2</sub>&nbsp;26%). In clinical studies the use of naproxen or other NSAIDs/Cox-2 inhibitors was not related to any clinically significant increase in adverse events.</p><p>Febuxostat can be co-administered with naproxen with no dose adjustment of febuxostat or naproxen being necessary.</p><p>&nbsp;</p><p><u>Inducers of glucuronidation</u></p><p>Potent inducers of UGT enzymes might possibly lead to increased metabolism and decreased efficacy of febuxostat. Monitoring of serum uric acid is therefore recommended 1-2 weeks after start of treatment with a potent inducer of glucuronidation. Conversely, cessation of treatment of an inducer might lead to increased plasma levels of febuxostat.</p><p>&nbsp;</p><p><u>Colchicine/indometacin/hydrochlorothiazide/warfarin</u></p><p>Febuxostat can be co-administered with colchicine or indomethacin with no dose adjustment of febuxostat or the co-administered active substance being necessary.</p><p>No dose adjustment is necessary for febuxostat when administered with hydrochlorothiazide.</p><p>No dose adjustment is necessary for warfarin when administered with febuxostat. Administration of febuxostat (80 mg or 120 mg once daily) with warfarin had no effect on the pharmacokinetics of warfarin in healthy subjects. INR and Factor VII activity were also not affected by the co-administration of febuxostat.</p><p>&nbsp;</p><p><u>Desipramine/CYP2D6 substrates</u></p><p>Febuxostat was shown to be a weak inhibitor of CYP2D6&nbsp;<em>in vitro.&nbsp;</em>In a study in healthy subjects, 120 mg febuxostat QD resulted in a mean 22% increase in AUC of desipramine, a CYP2D6 substrate indicating a potential weak inhibitory effect of febuxostat on the CYP2D6 enzyme&nbsp;<em>in vivo</em>. Thus, co-administration of febuxostat with other CYP2D6 substrates is not expected to require any dose adjustment for those compounds.</p><p>&nbsp;</p><p><u>Antacids</u></p><p>Concomitant ingestion of an antacid containing magnesium hydroxide and aluminium hydroxide has been shown to delay absorption of febuxostat (approximately 1 hour) and to cause a 32% decrease in C<sub>max</sub>, but no significant change in AUC was observed. Therefore, febuxostat may be taken without regard to antacid use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Data on a very limited number of exposed pregnancies have not indicated any adverse effects of febuxostat on pregnancy or on the health of the foetus/new born child. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development or parturition (see section 5.3). The potential risk for human is unknown. Febuxostat should not be used during pregnancy.</p><p>&nbsp;</p><p><u>Breastfeeding</u></p><p>It is unknown whether febuxostat is excreted in human breast milk. Animal studies have shown excretion of this active substance in breast milk and an impaired development of suckling pups. A risk to a suckling infant cannot be excluded. Febuxostat should not be used while breastfeeding.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>In animals, reproduction studies up to 48 mg/kg/day showed no dose-dependent adverse effects on fertility (see section 5.3). The effect of febuxostat on human fertility is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Somnolence, dizziness, paraesthesia and blurred vision have been reported with the use of Febuxostat. Patients should exercise caution before driving, using machinery or participating in dangerous activities until they are reasonably certain that febuxostat does not adversely affect performance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The most commonly reported adverse reactions in clinical trials (4,072 subjects treated at least with a dose from 10 mg to 300 mg) and post-marketing experience in gout patients are gout flares, liver function abnormalities, diarrhoea, nausea, headache, rash and oedema. These adverse reactions were mostly mild or moderate in severity. Rare serious hypersensitivity reactions to febuxostat, some of which were associated to systemic symptoms, and rare events of sudden cardiac death, have occurred in the post-marketing experience.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>Common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100) and rare (&ge;1/10,000 to &lt;1/1,000) adverse reactions occurring in patients treated with febuxostat are listed below.</p><p>The frequencies are based on studies and post-marketing experience in gout patients.</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Table 1: Adverse reactions in combined phase 3, long-term extension studies and post-marketing experience in gout patients</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p><u>Rare</u></p><p>Pancytopenia, thrombocytopenia, agranulocytosis*</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p><u>Rare</u></p><p>Anaphylactic reaction*, drug hypersensitivity*</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p><u>Uncommon</u></p><p>Blood thyroid stimulating hormone increased</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p><u>Rare</u></p><p>Blurred vision</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p><u>Common***</u></p><p>Gout flares</p><p><u>Uncommon</u></p><p>Diabetes mellitus, hyperlipidemia, decrease appetite, weight increase</p><p><u>Rare</u></p><p>Weight decrease, increase appetite, anorexia</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p><u>Uncommon</u></p><p>Libido decreased, insomnia</p><p><u>Rare</u></p><p>Nervousness</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p><u>Common</u></p><p>Headache</p><p><u>Uncommon</u></p><p>Dizziness, paraesthesia, hemiparesis, somnolence, altered taste, hypoaesthesia, hyposmia</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p><u>Rare</u></p><p>Tinnitus</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p><u>Uncommon</u></p><p>Atrial fibrillation, palpitations, ECG abnormal, left bundle branch block (see section Tumor Lysis Syndrome), sinus tachycardia (see section Tumor Lysis Syndrome)</p><p><u>Rare</u></p><p>Sudden cardiac death*</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p><u>Uncommon</u></p><p>Hypertension, flushing, hot flush, haemorrhage (see section Tumor Lysis Syndrome)</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory system disorders</p></td><td style="vertical-align:top"><p><u>Uncommon</u></p><p>Dyspnoea, bronchitis, upper respiratory tract infection, cough</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p><u>Common</u></p><p>Diarrhoea**, nausea</p><p><u>Uncommon</u></p><p>Abdominal pain, abdominal distension, gastro-oesophageal reflux disease, vomiting, dry mouth, dyspepsia, constipation, frequent stools, flatulence, gastrointestinal discomfort</p><p><u>Rare</u></p><p>Pancreatitis, mouth ulceration</p></td></tr><tr><td style="vertical-align:top"><p>Hepato-biliary disorders</p></td><td style="vertical-align:top"><p><u>Common</u></p><p>Liver function abnormalities**</p><p><u>Uncommon</u></p><p>Cholelithiasis</p><p><u>Rare</u></p><p>Hepatitis, jaundice*, liver injury*</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p><u>Common</u></p><p>Rash (including various types of rash reported with lower frequencies, see below)</p><p><u>Uncommon</u></p><p>Dermatitis, urticaria, pruritus, skin discolouration, skin lesion, petechiae, rash macular, rash maculopapular, rash papular</p><p><u>Rare</u></p><p>Toxic epidermal necrolysis*, Stevens-Johnson Syndrome*, angioedema*, drug reaction with eosinophilia and systemic symptoms*, generalized rash (serious)*, erythema, exfoliative rash, rash follicular, rash vesicular, rash pustular, rash pruritic*, rash erythematous, rash morbillifom, alopecia, hyperhidrosis</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p><u>Uncommon</u></p><p>Arthralgia, arthritis, myalgia, musculoskeletal pain, muscle weakness, muscle spasm, muscle tightness, bursitis</p><p><u>Rare</u></p><p>Rhabdomyolysis*, joint stiffness, musculoskeletal stiffness</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p><u>Uncommon</u></p><p>Renal failure, nephrolithiasis, haematuria, pollakiuria, proteinuria</p><p><u>Rare</u></p><p>Tubulointerstitial nephritis*, micturition urgency</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorder</p></td><td style="vertical-align:top"><p><u>Uncommon</u></p><p>Erectile dysfunction</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p><u>Common</u></p><p>Oedema</p><p><u>Uncommon</u></p><p>Fatigue, chest pain, chest discomfort</p><p><u>Rare</u></p><p>Thirst</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p><u>Uncommon</u></p><p>Blood amylase increase, platelet count decrease, WBC decrease, lymphocyte count decrease, blood creatine increase, blood creatinine increase, haemoglobin decrease, blood urea increase, blood triglycerides increase, blood cholesterol increase, haematocritic decrease, blood lactate dehydrogenase increased, blood potassium increase</p><p><u>Rare</u></p><p>Blood glucose increased, activated partial thromboplastin time prolonged, red blood cell count decrease, blood alkaline phosphatase increase, blood creatine phosphokinase increase*</p></td></tr></tbody></table><p>* Adverse reactions coming from post-marketing experience</p><p><em>**&nbsp;</em>Treatment-emergent non-infective diarrhoea and abnormal liver function tests in the combined Phase 3 studies are more frequent in patients concomitantly treated with colchicine.</p><p>*** See section 5.1 for incidences of gout flares in the individual Phase 3 randomized controlled studies.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>Rare serious hypersensitivity reactions to febuxostat, including Stevens-Johnson Syndrome, Toxic epidermal necrolysis and anaphylactic reaction/shock, have occurred in the post-marketing experience. Stevens-Johnson Syndrome and Toxic epidermal necrolysis are characterised by progressive skin rashes associated with blisters or mucosal lesions and eye irritation. Hypersensitivity reactions to febuxostat can be associated to the following symptoms: skin reactions characterised by infiltrated maculopapular eruption, generalised or exfoliative rashes, but also skin lesions, facial oedema, fever, haematologic abnormalities such as thrombocytopenia and eosinophilia, and single or multiple organ involvement (liver and kidney including tubulointerstitial nephritis) (see section 4.4).</p><p>Gout flares were commonly observed soon after the start of treatment and during the first months. Thereafter, the frequency of gout flare decreases in a time-dependent manner. Gout flare prophylaxis is recommended (see section 4.2 and 4.4).</p><p>&nbsp;</p><p><u>Tumor Lysis Syndrome</u></p><p><em>Summary of the safety profile</em></p><p>In the randomized, double-blind, Phase 3 pivotal FLORENCE (FLO-01) study comparing febuxostat with allopurinol (346 patients undergoing chemotherapy for haematologic malignancies and at intermediate-to-high risk of TLS), only 22 (6.4%) patients overall experienced adverse reactions, namely 11 (6.4%) patients in each treatment group. The majority of adverse reactions were either mild or moderate.</p><p>Overall, the FLORENCE trial did not highlight any particular safety concern in addition to the previous experience with febuxostat in gout, with the exception of the following three adverse reactions (listed above in table 1).</p><p>&nbsp;</p><p><u>Cardiac disorders:</u></p><p>Uncommon: Left bundle branch block, sinus tachycardia</p><p>&nbsp;</p><p><u>Vascular disorders:</u></p><p>Uncommon: haemorrhage</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&bull;&nbsp;&nbsp;Saudi Arabia</p><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/</p><p>&bull;&nbsp;&nbsp;Other GCC States</p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Patients with an overdose should be managed by symptomatic and supportive care.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antigout preparation, preparations inhibiting uric acid production, ATC code: M04AA03</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Uric acid is the end product of purine metabolism in humans and is generated in the cascade of hypoxanthine &rarr; xanthine &rarr; uric acid. Both steps in the above transformations are catalyzed by xanthine oxidase (XO). Febuxostat is a 2-arylthiazole derivative that achieves its therapeutic effect of decreasing serum uric acid by selectively inhibiting XO. Febuxostat is a potent, non-purine selective inhibitor of XO (NP-SIXO) with an&nbsp;<em>in vitro</em>&nbsp;inhibition K<sub>i</sub> value less than one nanomolar. Febuxostat has been shown to potently inhibit both the oxidized and reduced forms of XO. At therapeutic concentrations febuxostat does not inhibit other enzymes involved in purine or pyrimidine metabolism, namely, guanine deaminase, hypoxanthine guanine phosphoribosyltransferase, orotate phosphoribosyltransferase, orotidine monophosphate decarboxylase or purine nucleoside phosphorylase.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p><em>Gout</em></p><p>The efficacy of febuxostat was demonstrated in three Phase 3 pivotal studies (the two pivotal APEX and FACT studies, and the additional CONFIRMS study described below) that were conducted in 4101 patients with hyperuricaemia and gout. In each phase 3 pivotal study, febuxostat demonstrated superior ability to lower and maintain serum uric acid levels compared to allopurinol. The primary efficacy endpoint in the APEX and FACT studies was the proportion of patients whose last 3 monthly serum uric acid levels were &lt; 6.0 mg/dL (357 &micro;mol/L). In the additional phase 3 CONFIRMS study, for which results became available after the marketing authorisation for febuxostat was first issued, the primary efficacy endpoint was the proportion of patients whose serum urate level was &lt; 6.0 mg/dL at the final visit. No patients with organ transplant have been included in these studies (see section 4.2).</p><p>&nbsp;</p><p><em>APEX Study:</em> The Allopurinol and Placebo-Controlled Efficacy Study of Febuxostat (APEX) was a Phase 3, randomized, double-blind, multicenter, 28-week study. One thousand and seventy-two (1072) patients were randomized: placebo (n=134), febuxostat 80 mg QD (n=267), febuxostat 120 mg QD (n=269), febuxostat 240 mg QD (n=134) or allopurinol (300 mg QD [n=258] for patients with a baseline serum creatinine &le;1.5 mg/dL or 100 mg QD [n=10] for patients with a baseline serum creatinine &gt;1.5 mg/dL and &le;2.0 mg/dL). Two hundred and forty mg febuxostat (2 times the recommended highest dose) was used as a safety evaluation dose.</p><p>The APEX study showed statistically significant superiority of both the febuxostat 80 mg QD and the febuxostat 120 mg QD treatment arms&nbsp;<em>versus</em>&nbsp;the conventionally used doses of allopurinol 300 mg (n = 258) /100 mg (n = 10) treatment arm in reducing the sUA below 6 mg/dL (357 &micro;mol/L) (see Table 2 and Figure 1).</p><p>&nbsp;</p><p><em>FACT Study:</em> The Febuxostat Allopurinol Controlled Trial (FACT) Study was a Phase 3, randomized, double-blind, multicenter, 52-week study. Seven hundred sixty (760) patients were randomized: febuxostat 80 mg QD (n=256), febuxostat 120 mg QD (n=251), or allopurinol 300 mg QD (n=253).</p><p>The FACT study showed the statistically significant superiority of both febuxostat 80 mg and febuxostat 120 mg QD treatment arms&nbsp;<em>versus</em>&nbsp;the conventionally used dose of allopurinol 300 mg treatment arm in reducing and maintaining sUA below 6 mg/dL (357 &micro;mol/L).</p><p>&nbsp;</p><p>Table 2 summarises the primary efficacy endpoint results:</p><p>&nbsp;</p><p><strong>Table 2: Proportion of Patients with Serum Uric Acid Levels &lt;6.0 mg/dL (357 &micro;mol/L)</strong></p><p><strong>Last Three Monthly Visits</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Study</p></td><td style="vertical-align:bottom"><p>febuxostat 80 mg QD</p></td><td style="vertical-align:bottom"><p>febuxostat 120 mg QD</p></td><td style="vertical-align:bottom"><p>Allopurinol 300 / 100 mg QD<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>APEX</p><p>(28 weeks)</p></td><td style="vertical-align:top"><p>48%<sup>&nbsp;*</sup></p><p>(n=262)</p></td><td style="vertical-align:top"><p>65%<sup>&nbsp;*, #</sup></p><p>(n=269)</p></td><td style="vertical-align:top"><p>22%</p><p>(n=268)</p></td></tr><tr><td style="vertical-align:top"><p>FACT</p><p>(52 weeks)</p></td><td style="vertical-align:top"><p>53%<sup>*</sup></p><p>(n=255)</p></td><td style="vertical-align:top"><p>62%<sup>*</sup></p><p>(n=250)</p></td><td style="vertical-align:top"><p>21%</p><p>(n=251)</p></td></tr><tr><td style="vertical-align:top"><p>Combined Results</p></td><td style="vertical-align:top"><p>51%<sup>*</sup></p><p>(n=517)</p></td><td style="vertical-align:top"><p>63%<sup>*, #</sup></p><p>(n=519)</p></td><td style="vertical-align:top"><p>22%</p><p>(n=519)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>1&nbsp;</sup>results from subjects receiving either 100 mg QD (n=10: patients with serum creatinine &gt;1.5 and &le;2.0 mg/dL) or 300 mg QD (n=509) were pooled for analyses.</p><p>* p &lt; 0.001 vs allopurinol,&nbsp;<sup>#</sup>&nbsp;p &lt; 0.001 vs 80 mg</p></td></tr></tbody></table><p>&nbsp;</p><p>The ability of febuxostat to lower serum uric acid levels was prompt and persistent. Reduction in serum uric acid level to &lt;6.0 mg/dL (357 &micro;mol/L) was noted by the Week 2 visit and was maintained throughout treatment. The mean serum uric acid levels over time for each treatment group from the two pivotal Phase 3 studies are shown in Figure 1.</p><p><strong>&nbsp;</strong></p><p><strong>Figure 1: Mean Serum Uric Acid Levels in Combined Pivotal Phase 3 Studies</strong></p><p><img alt="" width="457" height="354" src="data:image/png;base64,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" /></p><p>Note:&nbsp;&nbsp;&nbsp; 509 patients received allopurinol 300 mg QD; 10 patients with serum creatinine &gt;1.5 and &lt; 2.0 mg/dL were dosed with 100 mg QD. (10 patients out of 268 in APEX study).</p><p>240 mg febuxostat was used to evaluate the safety of febuxostat at twice the recommended highest dose.</p><p>&nbsp;</p><p><em>CONFIRMS Study:</em> The CONFIRMS study was a Phase 3, randomized, controlled, 26-week study to evaluate the safety and efficacy of febuxostat 40 mg and 80 mg, in comparison with allopurinol 300 mg or 200 mg, in patients with gout and hyperuricaemia. Two thousand and two hundred-sixty nine (2269) patients were randomized: febuxostat 40 mg QD (n=757), febuxostat 80 mg QD (n=756), or allopurinol 300/200 mg QD (n=756). At least 65% of the patients had mild-moderate renal impairment (with creatinine clearance of 30-89 mL/min). Prophylaxis against gout flares was obligatory over the 26-week period.</p><p>The proportion of patients with serum urate levels of &lt; 6.0 mg/dL (357 &micro;mol/L) at the final visit, was 45% for 40 mg febuxostat, 67% for febuxostat 80 mg and 42% for allopurinol 300/200 mg, respectively.</p><p>&nbsp;</p><p><em>Primary endpoint in the sub-group of patients with renal impairment</em></p><p>The APEX Study evaluated efficacy in 40 patients with renal impairment (i.e., baseline serum creatinine &gt; 1.5 mg/dL and &le;2.0 mg/dL). For renally impaired subjects who were randomized to allopurinol, the dose was capped at 100 mg QD. febuxostat achieved the primary efficacy endpoint in 44% (80 mg QD), 45% (120 mg QD), and 60% (240 mg QD) of patients compared to 0% in the allopurinol 100 mg QD and placebo groups.</p><p>There were no clinically significant differences in the percent decrease in serum uric acid concentration in healthy subjects irrespective of their renal function (58% in the normal renal function group and 55% in the severe renal dysfunction group).</p><p>An analysis in patients with gout and renal impairment was prospectively defined in the CONFIRMS study, and showed that febuxostat was significantly more efficacious in lowering serum urate levels to &lt; 6 mg/dL compared to allopurinol 300 mg/200 mg in patients who had gout with mild to moderate renal impairment (65% of patients studied).</p><p>&nbsp;</p><p><em>Primary endpoint in the sub group of patients with sUA &ge; 10 mg/dL</em></p><p>Approximately 40% of patients (combined APEX and FACT) had a baseline sUA of &ge; 10 mg/dL. In this subgroup febuxostat achieved the primary efficacy endpoint (sUA &lt; 6.0 mg/dL at the last 3 visits) in 41% (80 mg QD), 48% (120 mg QD), and 66% (240 mg QD) of patients compared to 9% in the allopurinol 300 mg/100 mg QD and 0 % in the placebo groups.</p><p>In the CONFIRMS study, the proportion of patients achieving the primary efficacy endpoint (sUA &lt; 6.0 mg/dL at the final visit) for patients with a baseline serum urate level of &ge; 10 mg/dL treated with febuxostat 40 mg QD was 27% (66/249), with febuxostat 80 mg QD 49% (125/254) and with allopurinol 300 mg/200 mg QD 31% (72/230), respectively.</p><p>&nbsp;</p><p><em>Clinical Outcomes: proportion of patients requiring treatment for a gout flare</em></p><p>APEX study: During the 8-week prophylaxis period, a greater proportion of subjects in the febuxostat 120 mg (36%) treatment group required treatment for gout flare compared to febuxostat 80 mg (28%), allopurinol 300 mg (23%) and placebo (20%). Flares increased following the prophylaxis period and gradually decreased over time. Between 46% and 55% of subjects received treatment for gout flares from Week 8 and Week 28. Gout flares during the last 4 weeks of the study (Weeks 24-28) were observed in 15% (febuxostat 80, 120 mg), 14% (allopurinol 300 mg) and 20% (placebo) of subjects.</p><p>&nbsp;</p><p>FACT study: During the 8-week prophylaxis period, a greater proportion of subjects in the febuxostat 120 mg (36%) treatment group required treatment for a gout flare compared to both the febuxostat 80 mg (22%) and allopurinol 300 mg (21%) treatment groups. After the 8-week prophylaxis period, the incidences of flares increased and gradually decreased over time (64% and 70% of subjects received treatment for gout flares from Week 8-52). Gout flares during the last 4 weeks of the study (Weeks 49-52) were observed in 6-8% (febuxostat 80 mg, 120 mg) and 11% (allopurinol 300 mg) of subjects.</p><p>The proportion of subjects requiring treatment for a gout flare (APEX and FACT Study) was numerically lower in the groups that achieved an average post-baseline serum urate level &lt;6.0 mg/dL, &lt;5.0 mg/dL, or &lt;4.0 mg/dL compared to the group that achieved an average post-baseline serum urate level &ge;6.0 mg/dL during the last 32 weeks of the treatment period (Week 20-Week 24 to Week 49 - 52 intervals).</p><p>During the CONFIRMS study, the percentages of patients who required treatment for gout flares (Day 1 through Month 6) were 31% and 25% for the febuxostat 80 mg and allopurinol groups, respectively. No difference in the proportion of patients requiring treatment for gout flares was observed between the febuxostat 80 mg and 40 mg groups.</p><p>&nbsp;</p><p><em>Long-term, open label extension Studies</em></p><p>EXCEL Study (C02-021): The Excel study was a three years Phase 3, open label, multicenter, randomised, allopurinol-controlled, safety extension study for patients who had completed the pivotal Phase 3 studies (APEX or FACT). A total of 1,086 patients were enrolled: febuxostat 80 mg QD (n=649), febuxostat 120 mg QD (n=292) and allopurinol 300/100 mg QD (n=145). About 69 % of patients required no treatment change to achieve a final stable treatment. Patients who had 3 consecutive sUA levels &gt;6.0 mg/dL were withdrawn.</p><p>Serum urate levels were maintained over time (i.e. 91% and 93% of patients on initial treatment with febuxostat 80 mg and 120 mg, respectively, had sUA &lt;6 mg/dL at Month 36).</p><p>Three years data showed a decrease in the incidence of gout flares with less than 4% of patients requiring treatment for a flare (i.e. more than 96 % of patients did not require treatment for a flare) at Month 16-24 and at Month 30-36.</p><p>46% and 38%, of patients on final stable treatment of febuxostat 80 or 120 mg QD, respectively, had complete resolution of the primary palpable tophus from baseline to the Final Visit.</p><p>FOCUS Study (TMX-01-005) was a 5 years Phase 2, open-label, multicenter, safety extension study for patients who had completed the febuxostat 4 weeks of double blind dosing in study TMX-00-004. 116 patients were enrolled and received initially febuxostat 80 mg QD. 62% of patients required no dose adjustment to maintain sUA &lt;6 mg/dL and 38 % of patients required a dose adjustment to achieve a final stable dose.</p><p>The proportion of patients with serum urate levels of &lt;6.0 mg/dL (357 &micro;mol/L) at the final visit was greater than 80% (81-100%) at each febuxostat dose.</p><p>During the phase 3 clinical studies, mild liver function test abnormalities were observed in patients treated with febuxostat (5.0%). These rates were similar to the rates reported on allopurinol (4.2%) (see section 4.4). Increased TSH values (&gt;5.5 &micro;IU/mL) were observed in patients on long-term treatment with febuxostat (5.5%) and patients with allopurinol (5.8%) in the long term open label extension studies (see section 4.4).</p><p>&nbsp;</p><p><em>Post Marketing long term studies</em></p><p>CARES Study was a multicenter, randomized, double-blind, non inferiority trial comparing CV outcomes with febuxostat versus allopurinol in patients with gout and a history of major CV disease including MI, hospitalization for unstable angina, coronary or cerebral revascularization procedure, stroke, hospitalized transient ischemic attack, peripheral vascular disease, or diabetes mellitus with evidence of microvascular or macrovascular disease. To achieve sUA less than 6 mg/dL, the dose of febuxostat was titrated from 40 mg up to 80 mg (regardless of renal function) and the dose of allopurinol was titrated in 100 mg increments from 300 to 600 mg in patients with normal renal function and mild renal impairment and from 200 to 400 mg in patients with moderate renal impairment.</p><p>The primary endpoint in CARES was the time to first occurrence of MACE, a composite of non-fatal MI, non-fatal stroke, CV death and unstable angina with urgent coronary revascularization.</p><p>The endpoints (primary and secondary) were analysed according to the intention-to-treat (ITT) analysis including all subjects who were randomized and received at least one dose of double-blind study medication.</p><p>Overall 56.6% of patients discontinued trial treatment prematurely and 45% of patients did not complete all trial visits.</p><p>In total, 6,190 patients were followed for a median of 32 months and the median duration of exposure was 728 days for patients in febuxostat group (n 3098) and 719 days in allopurinol group (n 3092).</p><p>The primary MACE endpoint occurred at similar rates in the febuxostat and allopurinol treatment groups (10.8% vs. 10.4% of patients, respectively; hazard ratio [HR] 1.03; two-sided repeated 95% confidence interval [CI] 0.87-1.23).</p><p>In the analysis of the individual components of MACE, the rate of CV deaths was higher with febuxostat than allopurinol (4.3% vs. 3.2% of patients; HR 1.34; 95% CI 1.03-1.73). The rates of the other MACE events were similar in the febuxostat and allopurinol groups, i.e. non-fatal MI (3.6% vs. 3.8% of patients; HR 0.93; 95% CI 0.72-1.21), non-fatal stroke (2.3% vs. 2.3% of patients; HR 1.01; 95% CI 0.73-1.41) and urgent revascularization due to unstable angina (1.6% vs. 1.8% of patients; HR 0.86; 95% CI 0.59-1.26). The rate of all-cause mortality was also higher with febuxostat than allopurinol (7.8% vs. 6.4% of patients; HR 1.22; 95% CI 1.01-1.47), which was mainly driven by the higher rate of CV deaths in that group (see section 4.4).</p><p>Rates of adjudicated hospitalization for heart failure, hospital admissions for arrhythmias not associated with ischemia, venous thromboembolic events and hospitalization for transient ischemic attacks were comparable for febuxostat and allopurinol.</p><p>&nbsp;</p><p><em>Tumor Lysis Syndrome</em></p><p>The efficacy and safety of febuxostat in the prevention and treatment of Tumor Lysis Syndrome was evaluated in the FLORENCE (FLO-01) study. febuxostat showed a superior and faster urate lowering activity compared to allopurinol.</p><p>FLORENCE was a randomized (1:1), double blind, phase III, pivotal trial comparing febuxostat 120 mg once daily with allopurinol 200 to 600 mg daily (mean allopurinol daily dose [&plusmn; standard deviation]: 349.7 &plusmn; 112.90 mg) in terms of control of serum uric acid level. Eligible patients had to be candidates for allopurinol treatment or have no access to rasburicase. Primary endpoints were serum uric acid area under the curve (AUC sUA1-8) and change in serum creatinine (sC) level both from baseline to Day 8.</p><p>Overall, 346 patients with haematological malignancies undergoing chemotherapy and at intermediate / high risk of Tumor Lysis Syndrome were included. Mean AUC sUA1-8 (mgxh/dl) was significantly lower with febuxostat (514.0 &plusmn; 225.71 vs 708.0 &plusmn; 234.42; least square means difference: -196.794 [95% confidence interval: -238.600; -154.988]; p &lt; .0001). Furthermore, the mean serum uric acid level was significantly lower with febuxostat since the first 24 hours of treatment and at any following time point. No significant difference in mean serum creatinine change (%) occurred between febuxostat and allopurinol (-0.83 &plusmn; 26.98 vs -4.92 &plusmn; 16.70 respectively; least square means difference: 4.0970 [95% confidence interval: -0.6467; 8.8406]; p=0.0903). With regard to secondary endpoints, no significant difference was detected in terms of incidence of laboratory TLS (8.1% and 9.2% in febuxostat and allopurinol arm, respectively; relative risk: 0.875 [95% confidence interval: 0.4408; 1.7369]; p=0.8488) nor of clinical TLS (1.7% and 1.2% in febuxostat and allopurinol arm, respectively; relative risk: 0.994 [95% confidence interval: 0.9691; 1.0199]; p=1.0000). Incidence of overall treatment-emergent signs and symptoms and adverse drug reactions was 67.6% vs 64.7% and 6.4% vs 6.4% with febuxostat and allopurinol respectively. In the FLORENCE study febuxostat demonstrated a superior control of serum uric acid level compared to allopurinol in patients scheduled to receive the latter drug. No data comparing febuxostat with rasburicase are currently available.</p><p>The efficacy and safety of febuxostat has not been established in patients with acute severe TLS, e.g. in patients who failed on other urate lowering therapies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In healthy subjects, maximum plasma concentrations (C<sub>max</sub>) and area under the plasma concentration time curve (AUC) of febuxostat increased in a dose proportional manner following single and multiple doses of 10 mg to 120 mg. For doses between 120 mg and 300 mg, a greater than dose proportional increase in AUC is observed for febuxostat. There is no appreciable accumulation when doses of 10 mg to 240 mg are administered every 24 hours. Febuxostat has an apparent mean terminal elimination half-life (t<sub>1/2</sub>) of approximately 5 to 8 hours.</p><p>Population pharmacokinetic/pharmacodynamic analyses were conducted in 211 patients with hyperuricaemia and gout, treated with febuxostat 40-240 mg QD. In general, febuxostat pharmacokinetic parameters estimated by these analyses are consistent with those obtained from healthy subjects, indicating that healthy subjects are representative for pharmacokinetic/pharmacodynamic assessment in the patient population with gout.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>Febuxostat is rapidly (t<sub>max</sub>&nbsp;of 1.0-1.5 h) and well absorbed (at least 84%). After single or multiple oral 80 and 120 mg once daily doses, C<sub>max</sub>&nbsp;is approximately 2.8-3.2 &micro;g/mL, and 5.0-5.3 &micro;g/mL, respectively. Absolute bioavailability of the febuxostat tablet formulation has not been studied.</p><p>Following multiple oral 80 mg once daily doses or a single 120 mg dose with a high fat meal, there was a 49% and 38% decrease in C<sub>max</sub>&nbsp;and a 18% and 16% decrease in AUC, respectively. However, no clinically significant change in the percent decrease in serum uric acid concentration was observed where tested (80 mg multiple dose). Thus, febuxostat may be taken without regard to food.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The apparent steady state volume of distribution (V<sub>ss</sub>/F) of febuxostat ranges from 29 to 75 L after oral doses of 10-300 mg. The plasma protein binding of febuxostat is approximately 99.2%, (primarily to albumin), and is constant over the concentration range achieved with 80 and 120 mg doses. Plasma protein binding of the active metabolites ranges from about 82% to 91%.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Febuxostat is extensively metabolized by conjugation&nbsp;<em>via</em>&nbsp;uridine diphosphate glucuronosyltransferase (UDPGT) enzyme system and oxidation&nbsp;<em>via</em>&nbsp;the cytochrome P450 (CYP) system. Four pharmacologically active hydroxyl metabolites have been identified, of which three occur in plasma of humans.&nbsp;<em>In vitro</em>&nbsp;studies with human liver microsomes showed that those oxidative metabolites were formed primarily by CYP1A1, CYP1A2, CYP2C8 or CYP2C9 and febuxostat glucuronide was formed mainly by UGT 1A1, 1A8, and 1A9.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Febuxostat is eliminated by both hepatic and renal pathways. Following an 80 mg oral dose of&nbsp;<sup>14</sup>C-labeled febuxostat, approximately 49% of the dose was recovered in the urine as unchanged febuxostat (3%), the acyl glucuronide of the active substance (30%), its known oxidative metabolites and their conjugates (13%), and other unknown metabolites (3%). In addition to the urinary excretion, approximately 45% of the dose was recovered in the faeces as the unchanged febuxostat (12%), the acyl glucuronide of the active substance (1%), its known oxidative metabolites and their conjugates (25%), and other unknown metabolites (7%).</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>Following multiple doses of 80 mg of febuxostat in patients with mild, moderate or severe renal impairment, the C<sub>max</sub>&nbsp;of febuxostat did not change, relative to subjects with normal renal function. The mean total AUC of febuxostat increased by approximately 1.8-fold from 7.5 &mu;g h/mL in the normal renal function group to 13.2 &mu;g.h/mL in the severe renal dysfunction group. The C<sub>max</sub>&nbsp;and AUC of active metabolites increased up to 2- and 4-fold, respectively. However, no dose adjustment is necessary in patients with mild or moderate renal impairment.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>Following multiple doses of 80 mg of febuxostat in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment, the C<sub>max</sub>&nbsp;and AUC of febuxostat and its metabolites did not change significantly compared to subjects with normal hepatic function. No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C).</p><p>&nbsp;</p><p><u>Age</u></p><p>There were no significant changes observed in AUC of febuxostat or its metabolites following multiple oral doses of febuxostat in elderly as compared to younger healthy subjects.</p><p>&nbsp;</p><p><u>Gender</u></p><p>Following multiple oral doses of febuxostat, the C<sub>max</sub>&nbsp;and AUC were 24% and 12% higher in females than in males, respectively. However, weight-corrected C<sub>max</sub>&nbsp;and AUC were similar between the genders. No dose adjustment is needed based on gender.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effects in non-clinical studies were generally observed at exposures in excess of the maximum human exposure.</p><p>Pharmacokinetic modelling and simulation of rat data suggests that, when co-administered with febuxostat, the clinical dose of mercaptopurine/azathioprine should be reduced to 20% or less of the previously prescribed dose in order to avoid possible haematological effects (see section 4.4 and 4.5).</p><p>&nbsp;</p><p><u>Carcinogenesis, mutagenesis, impairment of fertility</u></p><p>In male rats, a statistically significant increase in urinary bladder tumours (transitional cell papilloma and carcinoma) was found only in association with xanthine calculi in the high dose group, at approximately 11 times human exposure. There was no significant increase in any other tumour type in either male or female mice or rats. These findings are considered a consequence of species specific purine metabolism and urine composition and of no relevance to clinical use.</p><p>A standard battery of test for genotoxicity did not reveal any biologically relevant genotoxic effects for febuxostat.</p><p>Febuxostat at oral doses up to 48 mg/kg/day was found to have no effect on fertility and reproductive performance of male and female rats.</p><p>There was no evidence of impaired fertility, teratogenic effects, or harm to the foetus due to febuxostat. There was high dose maternal toxicity accompanied by a reduction in weaning index and reduced development of offspring in rats at approximately 4.3 times human exposure. Teratology studies, performed in pregnant rats at approximately 4.3 times and pregnant rabbits at approximately 13 times human exposure did not reveal any teratogenic effects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Tablet core:</em></p><p>-&nbsp;&nbsp; Lactose monohydrate</p><p>-&nbsp;&nbsp; Microcrystalline cellulose</p><p>-&nbsp;&nbsp; Hypromellose</p><p>-&nbsp;&nbsp; Sodium lauryl sulfate</p><p>-&nbsp;&nbsp; Croscarmellose sodium</p><p>-&nbsp;&nbsp; Colloidal silicon dioxide</p><p>-&nbsp;&nbsp; Magnesium stearate</p><p><em>Tablet coat:</em></p><p>-&nbsp;&nbsp; Opadry Green</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p><p>Store in the original package.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/PE/PVDC with aluminum foil blisters.</p><p>Pack size: 30 Film-coated tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. BOX 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                16 March 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>